Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic CorrelatesJ. Clin. Oncol 2022 Mar 17;[EPub Ahead of Print], CH Lee, MH Voss, MI Carlo, YB Chen, M Zucker, A Knezevic, RA Lefkowitz, N Shapnik, C Dadoun, E Reznik, NJ Shah, CN Owens, DJ McHugh, DH Aggen, AL Laccetti, R Kotecha, DR Feldman, RJ Motzer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.